|
|
|
Volumn 118, Issue 1227, 2005, Pages
|
|
Evidence, economics, and emotions: The case for temozolomide
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALKYLATING AGENT;
TEMOZOLOMIDE;
DACARBAZINE;
DRUG DERIVATIVE;
ARTICLE;
CANCER GRADING;
CANCER MORTALITY;
CANCER PATIENT;
CANCER RELAPSE;
CANCER SURVIVAL;
CLINICAL TRIAL;
COST BENEFIT ANALYSIS;
DRUG CLASSIFICATION;
DRUG COST;
DRUG INDUSTRY;
ECONOMIC EVALUATION;
EMOTION;
EVIDENCE BASED MEDICINE;
GLIOBLASTOMA;
GLIOMA;
HEALTH CARE COST;
HUMAN;
NEW ZEALAND;
ONCOLOGY;
PROGNOSIS;
SURVIVAL RATE;
TREATMENT INDICATION;
TREATMENT OUTCOME;
DRUG APPROVAL;
ECONOMICS;
FEMALE;
MALE;
PUBLIC HEALTH;
ANTINEOPLASTIC AGENTS, ALKYLATING;
DACARBAZINE;
DRUG APPROVAL;
FEMALE;
GLIOBLASTOMA;
HUMANS;
MALE;
NATIONAL HEALTH PROGRAMS;
NEW ZEALAND;
|
|
EID: 29844447080
PISSN: 11758716
EISSN: 11758716
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (6)
|
|
References (0)
|
